BioNTech SE (NASDAQ: BNTX) — Company Overview, News & Financial Data
BioNTech focuses on mRNA technology to develop therapies for cancer and infectious diseases, including a COVID-19 vaccine in partnership with Pfizer.
BioNTech SE
BioNTech SE is a biotechnology company based in Germany that focuses on developing patient-specific therapies for cancer and infectious diseases. The company utilizes messenger RNA technology to design personalized immunotherapies, protein therapies, and cell therapies. BioNTech achieved global recognition for co-developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Its development pipeline includes targeted cancer treatments, antibody-drug conjugates, bispecific antibodies, and prophylactic vaccines targeting various infectious pathogens. The company operates research and manufacturing facilities in Germany and internationally, advancing multiple clinical-stage programs across oncology and infectious disease indications.
Snapshot
Operations
Products and/or services of BioNTech SE
- Prophylactic Vaccines: Production and distribution of messenger RNA vaccines targeting infectious pathogens, featuring a commercialized COVID-19 vaccine alongside clinical development programs for influenza, shingles, malaria, and tuberculosis targeting global healthcare markets.
- mRNA Cancer Immunotherapies: Development of individualized and off-the-shelf messenger RNA immunotherapies engineered to stimulate targeted T-cell responses against patient-specific neoantigens and shared tumor antigens across multiple solid tumor indications.
- Bispecific Immunomodulators: Development of clinical-stage dual-targeting antibody candidates designed to simultaneously block immune checkpoints such as PD-L1 and inhibit vascular endothelial growth factors, modulating immune microenvironments within advanced solid tumors.
- Antibody-Drug Conjugates: Clinical development of targeted biological therapies combining monoclonal antibodies with potent cytotoxic payloads, designed to selectively bind surface antigens expressed on tumor cells and deliver targeted cellular destruction.
- Engineered Cell Therapies: Specialized development and clinical bulk manufacturing of engineered cell therapies, including chimeric antigen receptor T-cell treatments, supported by dedicated manufacturing and quality control facilities located in Idar-Oberstein, Germany.
- Biopharmaceutical Manufacturing Facilities: Operation of integrated commercial and clinical production facilities, including a central manufacturing hub in Marburg, Germany, producing bulk messenger RNA drug substance, lipid nanoparticles, and formulated doses for global clinical supply.
BioNTech SE executive team
- Ugur SahinCo-Founder, CEO & Chair of the Management Board
- Ozlem TureciCo-Founder, Chief Medical Officer & Member of Management Board
- Ramon Zapata-GomezCFO & Member of Management Board
- Sierk PöttingMD, COO & Member of Management Board
- James Timothy Patrick RyanChief Legal & Business Officer and Member of the Management Board
- Annemarie HanekampChief Commercial Officer & Member of Management Board
- Kylie JimenezChief People Officer & Member of Management Board
- Lisa BirringerSenior Vice President of Global Financial Reporting & Accounting
- Douglas MaffeiVice President of Strategy & Investor Relations
- Jasmina AlatovicVice President Corporate Communications
Latest news about BioNTech SE
BioNTech Phase 3 trial meets endpoint amid safety concerns
United StatesPfizer BioNTech gets Canada vaccine authorization
United StatesBioNTech gotistobart reaches 18.5-month median survival
United StatesBioNTech to showcase data-rich lung cancer pipeline at ELCC 2026
United StatesBioNTech reports FY 2025 revenue of €2.87B and IFRS net loss of €1.14B
United States
Dividend history
Dividends per share paid by BioNTech SE, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2022 | — | — | — | $2.1110 |
Key financials
Reported results for BioNTech SE, in EUR.
- Market cap
- 22B
- Revenue (TTM)
- 2.6B
- P/E ratio
- —
- EPS (diluted, TTM)
- -7.8
- Dividend yield
- —
- Profit margin
- -63.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 2.8B | -623.9M | -1.1B | |
| 2.8B | -1.3B | -665.3M | |
| 3.8B | 690.4M | 930.3M | |
| 17.3B | 12.6B | 9.4B |